BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35188278)

  • 21. The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.
    Zhang R; Zhang Y; Zhang J; An T; Huang Y; Guo X; Januzzi JL; Cappola TP; Yin S; Wang Y; Zhou Q; Zou C; Ji S; Lv R
    PLoS One; 2014; 9(10):e110976. PubMed ID: 25347817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease.
    Vergaro G; Aimo A; Januzzi JL; Richards AM; Lam CSP; Latini R; Staszewsky L; Anand IS; Ueland T; Rocca HB; Bayes-Genis A; Lupón J; de Boer RA; Yoshihisa A; Takeishi Y; Gustafsson I; Eggers KM; Huber K; Gamble GD; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Troughton R; Doughty RN; Emdin M; Passino C
    J Cardiovasc Med (Hagerstown); 2022 Jan; 23(1):28-36. PubMed ID: 34839321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble ST2, BCN-Bio-HF calculator and MAGGIC-HF score in long-term risk prediction after an urgent visit for heart failure.
    Pérez-Sanz TM; Gómez-Salvador I; Codina P; Calvo Antón B; de la Torre Carpente MM; Redondo Bermejo B; Tapia Ballesteros C
    Heart Vessels; 2024 Mar; 39(3):216-225. PubMed ID: 37872307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction.
    Song Y; Li F; Xu Y; Liu Y; Wang Y; Han X; Fan Y; Cao J; Luo J; Sun A; Hu K; Zhou J; Ge J
    Int J Cardiol; 2020 Apr; 304():95-100. PubMed ID: 32019693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of multiple biomarkers for mortality prediction in patients with acute heart failure of ischemic and nonischemic etiology.
    Zhang M; Meng Q; Qi X; Han Q; Qi X; Wang F; Du B
    Biomark Med; 2018 Nov; 12(11):1207-1217. PubMed ID: 30499308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.
    Pascual-Figal DA; Ordoñez-Llanos J; Tornel PL; Vázquez R; Puig T; Valdés M; Cinca J; de Luna AB; Bayes-Genis A;
    J Am Coll Cardiol; 2009 Dec; 54(23):2174-9. PubMed ID: 19942089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnostic value of combining serum soluble ST2 and interleukin-33 for heart failure patients with preserved left ventricular ejection fraction].
    Luo NS; Zhang HF; Liu PM; Lin YQ; Huang TC; Yang Y; Wang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):198-203. PubMed ID: 28316175
    [No Abstract]   [Full Text] [Related]  

  • 28. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure.
    Gaggin HK; Szymonifka J; Bhardwaj A; Belcher A; De Berardinis B; Motiwala S; Wang TJ; Januzzi JL
    JACC Heart Fail; 2014 Feb; 2(1):65-72. PubMed ID: 24622120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
    Shelton RJ; Clark AL; Goode K; Rigby AS; Cleland JG
    Eur Heart J; 2006 Oct; 27(19):2353-61. PubMed ID: 16952921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Bansal N; Zelnick LR; Soliman EZ; Anderson A; Christenson R; DeFilippi C; Deo R; Feldman HI; He J; Ky B; Kusek J; Lash J; Seliger S; Shafi T; Wolf M; Go AS; Shlipak MG;
    Am J Kidney Dis; 2021 Jun; 77(6):907-919. PubMed ID: 33309861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
    Santema BT; Chan MMY; Tromp J; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; Ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA
    Clin Res Cardiol; 2020 Mar; 109(3):331-338. PubMed ID: 31263996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure.
    Tan ESJ; Chan SP; Liew OW; Chong JPC; Leong GKT; Yeo DPS; Ong HY; Jaufeerally F; Yap J; Sim D; Ng TP; Ling LH; Lam CSP; Richards AM
    Clin Chem; 2021 Jan; 67(1):216-226. PubMed ID: 33279970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure.
    Hamatani Y; Iguchi M; Ueno K; Aono Y; Esato M; Tsuji H; Wada H; Hasegawa K; Ogawa H; Abe M; Morita S; Akao M
    Heart; 2021 May; 107(9):705-712. PubMed ID: 33219109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.
    Morello A; Lloyd-Jones DM; Chae CU; van Kimmenade RR; Chen AC; Baggish AL; O'Donoghue M; Lee-Lewandrowski E; Januzzi JL
    Am Heart J; 2007 Jan; 153(1):90-7. PubMed ID: 17174644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ST2 as a novel prognostic marker in end-stage renal disease patients on hemodiafiltration.
    Homsak E; Ekart R
    Clin Chim Acta; 2018 Feb; 477():105-112. PubMed ID: 29221927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.
    Pan W; Yang D; Yu P; Yu H
    BMC Cardiovasc Disord; 2020 Apr; 20(1):208. PubMed ID: 32354356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for Predicting the Occurrence and Progression of Atrial Fibrillation: Soluble Suppression of Tumorigenicity 2 Protein and Tissue Inhibitor of Matrix Metalloproteinase-1.
    Sun WP; Du X; Chen JJ
    Int J Clin Pract; 2022; 2022():6926510. PubMed ID: 36683600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocardial fibrosis combined with NT-proBNP improves the accuracy of survival prediction in ADHF patients.
    Yao Y; Feng L; Sun Y; Wang S; Sun J; Hu B
    BMC Cardiovasc Disord; 2021 May; 21(1):264. PubMed ID: 34049488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Midregional N-Terminal Pro-Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study.
    Badoz M; Serzian G; Favoulet B; Sellal JM; De Chillou C; Hammache N; Laurent G; Mebazaa A; Ecarnot F; Bardonnet K; Seronde MF; Schiele F; Meneveau N
    J Am Heart Assoc; 2021 Jul; 10(13):e020917. PubMed ID: 34187182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure.
    Corell P; Gustafsson F; Kistorp C; Madsen LH; Schou M; Hildebrandt P
    Int J Cardiol; 2007 May; 117(3):395-402. PubMed ID: 16919342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.